Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms.

Blood Adv · 2022 · PMC8791578 · PMID 34644397

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In comparison with AML with inv(16), m DDX41 AML showed a trend to better OS; however, statistical significance was not achieved (2-year OS, 100% vs 84%; P = .2), supporting at least noninferior clinical outcome ( Figure 1C ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.